Identification of plasma lipid species as promising diagnostic markers for prostate cancer

BMC Medical Informatics and Decision Making

Masaki Nasu¹  Mayumi Jijiwa¹  Youping Deng¹  Jicai Zhang²  Junmei Ai³  Shengming Dai⁴  Xiaoli Chen⁵  Bin Jiang⁶  Yong Zhu⁷  Gang Huang⁸ 

[1] Bioinformatics Core, Department of Quantitative Health Sciences, University of Hawaii John A. Burns School of Medicine, Honolulu, HI, USA;Department of Laboratory Medicine, Shiyan Taihe Hospital, College of Biomedical Engineering, Hubei University of Medicine, 442000, Shiyan, Hubei, P. R. China;Department of Medicine, Rush University Medical Center, Chicago, IL, USA;Medical Science Laboratory, the Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi, China;Bioinformatics Core, Department of Quantitative Health Sciences, University of Hawaii John A. Burns School of Medicine, Honolulu, HI, USA;Medical Science Laboratory, the Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi, China;Department of Medicine, Rush University Medical Center, Chicago, IL, USA;National Medical Centre of Colorectal Disease, The Third Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, P. R. China;National Medical Centre of Colorectal Disease, The Third Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, P. R. China;Department of Medicine, Rush University Medical Center, Chicago, IL, USA;Shanghai Key Laboratory for Molecular Imaging, Shanghai University of Medicine and Health Sciences, 201318, Shanghai, P. R. China;

关键词: Lipidomics;    Prostate cancer;    Diagnosis;    Metabolic pathway;    LC-ESI-MS/MS;   

DOI  :  10.1186/s12911-020-01242-7

来源: Springer

【 摘 要 】

BackgroundProstate cancer is a very common and highly fatal in men. Current non-invasive detection methods like serum biomarker are unsatisfactory. Biomarkers with high accuracy for diagnostic of prostate cancer are urgently needed. Many lipid species have been found related to various cancers. The purpose of our study is to explore the diagnostic value of lipids for prostate cancer.ResultsUsing triple quadruple liquid chromatography electrospray ionization tandem mass spectrometry, we performed lipidomics profiling of 367 lipids on a total 114 plasma samples from 30 patients with prostate cancer, 38 patients with benign prostatic hyperplasia (BPH), and 46 male healthy controls to evaluate the lipids as potential biomarkers in the diagnosis of prostate cancer. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database was used to construct the potential mechanism pathway. After statistical analysis, five lipids were identified as a panel of potential biomarkers for the detection of prostate cancer between prostate cancer group and the BPH group; the sensitivity, specificity, and area under curve (AUC) of the combination of these five lipids were 73.3, 81.6%, and 0.800, respectively. We also identified another panel of five lipids in distinguishing between prostate cancer group and the control group with predictive values of sensitivity at 76.7%, specificity at 80.4%, and AUC at 0.836, respectively. The glycerophospholipid metabolism pathway of the selected lipids was considered as the target pathway.ConclusionsOur study indicated that the identified plasma lipid biomarkers have potential in the diagnosis of prostate cancer.

【 授权许可】

CC BY